tbuckley/cabot-search huggingface dataset:
The Antiretroviral Agent Nelfinavir Mesylate
Authors: Cecilia G. Sanchez, Steven V. Molinski, Rafael Gongora, Meredith Sosulski, Taylor Fuselier, Stephen S. MacKinnon, Debasis Mondal, Joseph A. Lasky
Journal: Arthritis & Rheumatology (2017)

Objective Transforming growth factor β1 ( TGF β1) is considered a key factor in fibrogenesis, and blocking TGF β1 signaling pathways diminishes fibrogenesis in animal models. The objective of this study was to determine whether nelfinavir mesylate ( NFV ), a drug approved by the Food and Drug Administration ( FDA ) for treating HIV infection, could be repurposed to treat pulmonary fibrosis in patients with systemic sclerosis ( SS c). Methods Normal human lung, ventricular, and skin fibroblasts as well as lung fibroblasts from SS c patients were used to determine the effects of NFV on fibroblast‐to‐myofibroblast differentiation mediated by TGF β1. The efficacy of NFV was also evaluated in an animal model of SS c (bleomycin‐induced pulmonary fibrosis). In addition, in silico analysis was performed to determine novel off‐target effects of NFV . Results NFV inhibited TGF β1‐mediated fibroblast‐to‐myofibroblast differentiation in lung fibroblasts through inhibition of the TGF β1 canonical pathway. NFV also inhibited differentiation of skin and ventricular fibroblasts and adipocyte precursors into myofibroblasts. Activation of the TGF β1/mechanistic target of rapamycin pathway inhibited autophagy in lung fibroblasts, favoring collagen deposition, and NFV counteracted this effect in a dose‐dependent manner. Moreover, NFV significantly reduced lung injury and collagen deposition in an animal model of SS c. In silico analysis of NFV binding proteins revealed new putative beneficial mechanisms of action, consistent with known common pathways in fibrogenesis. Conclusion NFV abrogates TGF β1‐mediated fibroblast‐to‐myofibroblast differentiation and pulmonary fibrosis through off‐target protein binding, a finding that supports consideration of this FDA ‐approved medication as an antifibrotic agent.
A case of sigmoid volvulus
Authors: Aikaterini Leventi, Thomas Frederick James Clifford, Amy Arnold, Charles H Knowles, Joanne E Martin
Journal: Gut (2018)

A 53-year-old man was admitted with a 2-week history of bowel obstruction on a background of gradually worsening dyspeptic symptoms associated with vomiting and weight loss. He was under regular gastroenterology review for Barrett’s oesophagus and had a recent endoscopic diagnosis of megaduodenum (mainly D1 dilatation) confirmed by barium study (figure 1). He was also known to have bladder emptying problems and an enlarged bladder. His mother died at age 28 due to ‘megacolon’, and he has a monozygotic twin brother with Barrett’s oesophagus.



Figure 1 
Barium meal and follow through confirmed dilation of the duodenum with normal small …
The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity
Authors: Michal Abraham, Galia Oberkovitz, Baruch Bulvik, Klein Shiri, Hanna Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, Abi Vainstein, Eyal Benami, Rotem Golan, Eithan Galun, Yoseph Caraco, Reuven Or, Amnon Peled
Journal: Blood (2017)
Platelet Activation is Increased in IgE-mediated Systemic Anaphylaxis but not in IgE-mediated Oral Antigen-induced Anaphylaxis in Mice
Authors: Andrew T. Dang, Yanfen Yang, Lisa Waggoner, Amnah Yamani, Taeko Noah, Jazib Uddin, Simon P. Hogan
Journal: Journal of Allergy and Clinical Immunology (2018)
BQ323636.1, a Novel Splice Variant to<i>NCOR</i>2, as a Predictor for Tamoxifen-Resistant Breast Cancer
Authors: Chun Gong, Ellen P.S. Man, Ho Tsoi, Terence K.W. Lee, Paul Lee, Sai-Ting Ma, Lai-San Wong, Mai-Yee Luk, Emad A. Rakha, Andrew R. Green, Ian O. Ellis, Eric W.-F. Lam, Kwok-Leung Cheung, Ui-Soon Khoo
Journal: Clinical Cancer Research (2018)

Purpose: Adjuvant tamoxifen treatment revolutionized the management of estrogen receptor (ER)-positive breast cancers to prevent cancer recurrence; however, drug resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen resistance are not fully understood, and no robust biomarker is available to reliably predict those who will be resistant. Here, we study BQ323636.1, a novel splice variant of the NCOR2 gene, and evaluate its efficacy in predicting tamoxifen resistance in patients with breast cancer.Experimental Design: A monoclonal anti-BQ323636.1 antibody that specifically recognizes the unique epitope of this splice variant was generated for in vitro mechanistic studies and for in vivo analysis by immunohistochemistry on tissue microarrays of two independent cohorts of 358 patients with more than 10 years clinical follow-up data, who had ER-positive primary breast cancer and received adjuvant tamoxifen treatment. An orthotopic mouse model was also used.Results: Overexpression of BQ323636.1 conferred resistance to tamoxifen in both in vitro and in an orthotopic mouse model. Mechanistically, coimmunoprecipitation showed BQ323636.1 could bind to NCOR2 and inhibit the formation of corepressor complex for the suppression of ER signaling. Nuclear BQ3232636.1 overexpression in patients samples was significantly associated with tamoxifen resistance (P = 1.79 × 10-6, sensitivity 52.9%, specificity 72.0%). In tamoxifen-treated patients, nuclear BQ323636.1 overexpression was significantly correlated with cancer metastasis and disease relapse. Nuclear BQ323636.1 was also significantly associated with poorer overall survival (P = 1.13 × 10-4) and disease-specific survival (P = 4.02 × 10-5).Conclusions: These findings demonstrate that BQ323636.1 can be a reliable biomarker to predict tamoxifen resistance in patients with ER-positive breast cancer. Clin Cancer Res; 24(15); 3681-91. ©2018 AACRSee related commentary by Jordan, p. 3480.
Abstract #4790: Subsets of Mesenchymal Stem Cells Correlate With Breast Cancer-Propagating Cells in Bone Marrow
Authors: Ugo De Giorgi, Anthony Lucci, Evan Cohen, Hui Gao, Michal Mego, Changping Li, Massimo Cristofanilli, James Reuben
Journal: Cancer Research (2009)

Background. Bone marrow-derived mesenchymal stem cells (BM-MSC) have shown several tumor growth promoting functions, including expression of growth factors, promotion of tumor vessel formation and creation of tumor stem cell niches. Breast cancer-propagating cells (BCPC) with a phenotype of CD44+CD24low/- have been detected within the disseminated tumor cell (CD326+) subset in BM of early breast cancer patients CD200, CD271, and GD2 have been proposed as markers for BM-MSC; however, little data are available on phenotypes of these cells in humans. In this preliminary study, we try to elucidate the relationship between BM-MSC and BCPC. Methods. As part of a continuing study at the University of Texas M.D. Anderson Cancer Center, 10 mL of BM were collected from the iliac crest of 12 primary breast cancer patients. Mononuclear cells from bilateral aspirates were combined and analyzed for the presence of BCPC, as defined by the phenotype, CD326+CD45-CD44+CD24low/- , acquired by multi-parameter FACS analysis. The results are reported as number of BCPC per 106 bone marrow mononuclear cells (BM-MNC). Within the CD326-depleted BM-MNC population, BM-MSC were identified as CD200+, GD2+ or CD271+ but negative for CD45 and CD34. Pearson\#8217;s test was used to determine correlations between BM-MSC and BCPC. Results. All 12 BM samples contained disseminated tumor cells with BCPC. The number of CD45- GD2+ expressing cells correlated with the number of CD271+ cells (Pearson correlation r = .660, p = 0.019), but neither marker was correlated with the number of CD45- cells expressing CD200 (r = -0.056, p= .862 and r = -0.278 p = 0.381 respectively) . Only BM-MSC expressing both GD2 and CD271 correlated with the number of BCPC (CD45-GD2+CD200+CD271+ Pearson correlation r = 0.658, p = 0.020; CD45-GD2+CD271+ Pearson correlation r = 0.616, p = 0.033). Conclusion. The presence of BCPC in the BM is related to subsets of BM-MSC that expresses CD271 and GD2, but not CD200. Further studies will investigate the clinico-biological relevance of this preliminary observation.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4790.
Abstract 19965: Emergency Medical Technicians Are Often Consulted on Termination of Resuscitation, and Will Terminate Resuscitation Based on Controversial Single Factors
Authors: Troels Mygind-Klausen, Kasper G. Lauridsen, Henrik Bødker, Bo Løfgren
Journal: Circulation (2016)

Introduction: Many out-of-hospital cardiopulmonary resuscitation (CPR) attempts have to be terminated. Previous studies have investigated knowledge on abandoning resuscitation among physicians. In ...
Disparities in Live Donor Kidney Transplantation
Authors: Colleen L. Jay, Francisco G. Cigarroa
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcome of Children with Acute Leukemia Given Allogeneic HSCT Either from an Unrelated Donor or from an HLA-Partially Matched Relative after αβ-T Cell/B-Cell Depletion: A Multicenter, Retrospective, Comparative Analysis of the AIEOP Network
Authors: Bertaina Alice, Zecca Marco, Buldini Barbara, Sacchi Nicoletta, Algeri Mattia, Saglio Francesco, Perotti Cesare, Anna Maria Gallina, Lanino Edoardo, Prete Arcangelo, Anna Paola Iori, Tumino Manuela, Favre Claudio, Simone Cesaro, Ripaldi Mimmo, Casazza Gabriella, Rabusin Marco, Francesca Del Bufalo, Balduzzi Adriana, Franca Fagioli, Franco Locatelli
Journal: Blood (2017)
Differential Expression of IL-17 Correlates with Clinical and Pathological Features of ITP
Authors: Naoko Okamoto, Mayumi Homma, Yukiko Kawaguchi, Nobuyuki Kabasawa, Yui Uto, Shohei Yamamoto, Norimichi Hattori, Eisuke Shiozawa, Toshiko Yamochi, Keiichi Isoyama, Tsuyoshi Nakamaki, Masafumi Takimoto
Journal: Blood (2017)
Abstract 355: CardioClusters: Harnessing the Power of Multi-lineage Cardiac Stem Cells
Authors: Megan M Monsanto, Kevin White, Kristina Fisher, Jessica Wang, Mark A Sussman
Journal: Circulation Research (2017)

Existing approaches to modify stem cells for myocardial regeneration desperately need innovative solutions that enhance cell engraftment and persistence. Although this deficiency has been attacked through combinatorial stem cell delivery, there is no evidence that these stem cell injections provide for direct cellular crosstalk to promote stem cell survival and proliferation. Therefore, we created a CardioCluster, a 3D microenvironment consisting of three defined cell populations from the human heart: c-kit + cardiac progenitor cells (CPCs), CD90 + /CD105 + mesenchymal stem cells (MSCs) and CD133 + endothelial progenitor cells (EPCs). The size of the CardioCluster can be controlled by the quantity of cells used to create the cluster, allowing them to be infused into the heart without being reduced to single cell suspensions as is the case for cardiosphere-derived cells where the structural and cell-cell contact information is lost when delivered. Unlike cardiospheres, these cardiac cells are combined into a rationally designed cluster with MSCs and CPCs in the central core and EPCs forming the outer layer. EPCs play a vital role in forming neovasculature that will connect the CardioClusters to living heart tissue not damaged by ischemia and allow for revascularization of the damaged myocardium. In vitro we have shown that EPCs are better able to form tubular networks on matrigel-coated plates compared to either CPCs or MSCs. MSCs reinforce the 3D structure by releasing growth factors that attract and maintain cells within the cluster, as well as release immunomodulatory signaling factors. Upon induction of an oxidative stress by hydrogen peroxide CardioClusters show improved cell survival with a lower percentage of apoptotic and/or necrotic cell populations compared to the three populations individually. Upon myocardial injection CardioClusters have been shown to maintain their 3D structural integrity. Future directions will be to assess long-term engraftment and regenerative potential in a mouse model of myocardial infarction.
Frequency of germline patghogenic mutation in breast cancer patients at high risk hereditary cancer.
Authors: Hee-Chul Shin, Wonshik Han, Han-Byoel Lee, Hyeong-Gon Moon, Eunshin Lee, Dong Young Noh
Journal: Journal of Clinical Oncology (2017)

e13110 Background: Next-generation sequencing technology allows the simultaneous sequencing of multiple target genes. We developed a gene panel containing 64 genes which were associated with various hereditary cancers. This study was performed to evaluate the frequency of pathogenic mutations associated with hereditary cancer among Korean patients at high risk hereditary breast cancer using multi-gene sequencing panel. Methods: A total of 252 breast cancer patients with high-risk hereditary cancer were included. Among them, 179 patients (71.0%) had multiple primary cancers including breast cancer, 27 patients (10.7%) were diagnosed with bilateral breast cancer at age 40 or younger. Thirty-five patients (13.9%) had breast cancer family history of more than 2 relatives. With the 64 gene panel, sequence variants were detected by next-generation sequencing technology. Results: Sixty seven patients (26.8%) were found to have 77 germline pathogenic mutations, 12 in BRCA1, 13 in BRCA2, 9 in CDH1, 3 in FH, 5 in MSH2, 2 in MSH6, 4 in NAT1, 6 in PTCH1, 3 in RAD51, 7 in RET, 4 in SPINK1, 3 in TP53 and one each in ALK, BRIP1, CHEK2, MLH2, MUTYH, and PTEN. In 20 patients (4.0%), 2 (n = 9) or 3 (n = 1) pathogenic mutations were detected. In 227 patients with BRCA1/2 negative, CDH1 (n = 7), RET (n = 7), PTCH1 (n = 5), and MSH2 (n = 5) were the most prevalent pathogenic mutations. Conclusions: The 64 gene panel detected germline pathogenic mutations in 26.8% of Korean breast cancer patients with feature of hereditary cancer. Mutations of BRCA1, BRCA2, CDH1, RET, and PTCH1 were the most prevalent variants.Mutation carriers were considered as high risk to develop malignancy and recommended to receive genetic counseling and intensive cancer screening.
A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes
Authors: Isabelle Serr, Martin G. Scherm, Adam M. Zahm, Jonathan Schug, Victoria K. Flynn, Markus Hippich, Stefanie Kälin, Maike Becker, Peter Achenbach, Alexei Nikolaev, Katharina Gerlach, Nicole Liebsch, Brigitta Loretz, Claus-Michael Lehr, Benedikt Kirchner, Melanie Spornraft, Bettina Haase, James Segars, Christoph Küper, Ralf Palmisano, Ari Waisman, Richard A. Willis, Wan-Uk Kim, Benno Weigmann, Klaus H. Kaestner, Anette-Gabriele Ziegler, Carolin Daniel
Journal: Science Translational Medicine (2018)

A miRNA181a/NFAT5 signaling axis promotes immune activation and interferes with the induction of regulatory T cells in islet autoimmunity.
t(9;22)(q34;q11) with the BCR-ABL mBCR fusion gene transcript - in: "Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program"
Authors: J. L. E. Aerts, D. Grimwade, P. Vandekerckhove, A. Navarrete, R. Flora, J. Krauter, G. Heil, S. Viehmann, C. Preudhomme, N. Grardel Duflos, F. Pane, Mariano Intrieri, F. Salvatore, N. Cross, J. Kaeda, M. Malec, A. Porwitt, Y. Toyron, Mj Mozziconacci, M. Lafage Pochitaloff
Journal: Leukemia (2003)
Recurrent Circuitry for Balancing Sleep Need and Sleep
Authors: Jeffrey M. Donlea, Diogo Pimentel, Clifford B. Talbot, Anissa Kempf, Jaison J. Omoto, Volker Hartenstein, Gero Miesenböck
Journal: Neuron (2018)

Sleep-promoting neurons in the dorsal fan-shaped body (dFB) of Drosophila are integral to sleep homeostasis, but how these cells impose sleep on the organism is unknown. We report that dFB neurons communicate via inhibitory transmitters, including allatostatin-A (AstA), with interneurons connecting the superior arch with the ellipsoid body of the central complex. These "helicon cells" express the galanin receptor homolog AstA-R1, respond to visual input, gate locomotion, and are inhibited by AstA, suggesting that dFB neurons promote rest by suppressing visually guided movement. Sleep changes caused by enhanced or diminished allatostatinergic transmission from dFB neurons and by inhibition or optogenetic stimulation of helicon cells support this notion. Helicon cells provide excitation to R2 neurons of the ellipsoid body, whose activity-dependent plasticity signals rising sleep pressure to the dFB. By virtue of this autoregulatory loop, dFB-mediated inhibition interrupts processes that incur a sleep debt, allowing restorative sleep to rebalance the books. VIDEO ABSTRACT.
Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program Accreditation
Authors: Anthony T. Petrick, John Morton, Stacey Brethauer
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Authors: Fengchun Zhang, Sang-Cheol Bae, Damon Bass, Myron Chu, Sally Egginton, David Gordon, David A Roth, Jie Zheng, Yoshiya Tanaka
Journal: Annals of the Rheumatic Diseases (2018)

Intravenous belimumab plus standard of care (SoC) is approved in the USA and Europe for treatment of active, autoantibody-positive systemic lupus erythematosus (SLE).This phase III, multicentre, randomised, double-blind, placebo-controlled study (BEL113750; NCT01345253) was conducted in 49 centres across China, Japan and South Korea (May 2011-September 2015). Patients with SLE were randomised 2:1 to intravenous belimumab 10 mg/kg or placebo, plus SoC, every 4 weeks until Week 48. The primary endpoint was the SLE Responder Index (SRI) 4 response rate at Week 52. Secondary endpoints were the percentage of patients with ≥4 point reduction in Safety of Oestrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), SRI7, time to first severe flare and number of days prednisone (or equivalent) dose ≤7.5 mg/day and/or reduced by 50% from baseline. Safety was assessed.The modified intent-to-treat population included 677 patients (belimumab n=451, placebo n=226). At Week 52, the SRI4 response rate was higher with belimumab versus placebo (53.8% vs 40.1%; OR: 1.99 (95% CI: 1.40, 2.82; P=0.0001)). The percentages of patients with a ≥4 point reduction in SELENA-SLEDAI and an SRI7 response were significantly greater for belimumab versus placebo. Patients in the belimumab group had a 50% lower risk of experiencing a severe flare than those receiving placebo (P=0.0004). In patients with baseline prednisone dose >7.5 mg/day, there was a significant reduction in steroid use favouring belimumab (P=0.0228). The incidence of adverse events was similar between groups.In patients with SLE from North East Asia, belimumab significantly improved disease activity, while reducing prednisone use, with no new safety issues.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
Authors: Meletios A. Dimopoulos, Darrell J. White, Lofti Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan Schecter, Philippe Moreau
Journal: Blood (2017)
Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma
Authors: Kazuna Tanba, Yoshiaki Chinen, Hitoji Uchiyama, Nobuhiko Uoshima, Kazuho Shimura, Shinichi Fuchida, Miki Kiyota, Mitsushige Nakao, Yuji Shimura, Tsutomu Kobayashi, Shigeo Horiike, Katsuya Wada, Chihiro Shimazaki, Hiroto Kaneko, Yutaka Kobayashi, Masafumi Taniwaki, Junya Kuroda
Journal: Blood Cancer Journal (2018)